Nanoparticle-based targeted therapy through EGFR tyrosine kinase inhibitors and their recent advances in lung cancer therapy
The emergence and subsequent advancement of nanotechnology in recent years have greatly benefited the healthcare sector, particularly in the treatment of cancer. As per study, major fatalities are related to the lung cancer. For many years, oral tyrosine kinase inhibitors (TKIs) against the epiderma...
Saved in:
Main Authors: | Priyanka S. Waghmare (Author), Anuruddha R. Chabukswar (Author), Kunal G. Raut (Author), Bhagyashree Gaikwad-Pawar (Author), Swati C. Jagdale (Author) |
---|---|
Format: | Book |
Published: |
Open Exploration Publishing Inc.,
2024-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
by: Zhe Zhang, et al.
Published: (2019) -
Primary Resistance to EGFR Tyrosine Kinase Inhibitors (TKIs): Contexts and Comparisons in EGFR-Mutated Lung Cancer
by: Keigo Kobayashi
Published: (2023) -
Advances in nanotechnology-based delivery systems for EGFR tyrosine kinases inhibitors in cancer therapy
by: Xiaohan Zhou, et al.
Published: (2020) -
Mechanisms of resistance to EGFR tyrosine kinase inhibitors
by: Lihua Huang, et al.
Published: (2015) -
Tyrosine kinase inhibitors for EGFR- and ALK-mutated non-small cell lung cancer
by: Jonathan R. Thompson, et al.
Published: (2016)